Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Sep 08, 2023 8:45pm
130 Views
Post# 35627217

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Well?

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Well?Dad was on capecitabine and took it orally for the last 7 years.  I felt like the physician's assistant was a little surprised by how long he had been on it.  While MD Anderson acknowledged that the 3 drugs he's taking again wouldn't have been their initial recommendation, they weren't clear on what they would've recommended.  Sounded to me that neuroendocrine tumors don't respond well to traditional chemotherapy, which is what I believe dad has been recommended.  I didn't understand what non-traditional chemotherapy is or means, but I was under the impression that the drugs he's taking now are more for carcinoma (carcinoid) tumor types.  Because he responded well to what was done before, they are going to initially try it again.  It also sounded like immunotherapy, radiation, and maybe a clinical trial were other options should they need to make adjustments.
<< Previous
Bullboard Posts
Next >>